Excreted Unchanged %
5-33
Half-Life (Normalesrd) Hours
4-22/No data
Plasma Protein Binding %
95
Volume Of Distribution L/Kg
0.6 (10-31 L/m2)
Dose For Normal Renal Function
45 mg/m2 q24h
Second Dose
Second Dose: adjust based on hematologicparameters
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100%[D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
No data: 50-100%; (see notes)[D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
Avoid[D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: No data
Supplement For Dialysis [Recommendation Level]: Pd
PD: No data
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 30-50,[D]
References
Ho DH, Covington WP, Legha SS, Newman RA, Krakoff IH. Clinical pharmacology of trimetrexate. Clin Pharmacol Ther. 1987; 42: 351-6. [PMID: 2957140] / Marshall JL, DeLap RJ. Clinical pharmacokinetics and pharmacology of trimetrexate. Clin Pharmacokinet. 1994; 26: 190-200. [PMID: 8194282]
Toxicity Notes
Must administer with leucovorin (folinic acid). Avoid if serum creatinine >2.5 mg/dL.